Perspective Therapeutics(US:CATX) Globenewswire·2026-01-09 12:00Core Viewpoint - Perspective Therapeutics, Inc. announced updated interim results from its Phase 1/2a clinical trial of [Pb]VMT-α-NET for treating unresectable or metastatic neuroendocrine tumors, presented at the 2026 ASCO Gastrointestinal Cancers Symposium [1] Clinical Trial Results - The interim results are based on a data cut-off date of December 10, 2025, including safety data from 56 patients across three dose cohorts and efficacy analysis from two patients in Cohort 1 and 23 patients in Cohort 2 [2] - Updated interim results show that [Pb]VMT-α-NET continues to be well-tolerated with no reports of dose limiting toxicities (DLTs) or serious treatment-related complications [6][7] - Objective response rate in Cohort 2 is 39%, with 9 patients showing response according to RECIST v1.1, including 8 previously confirmed responders [6][7] Safety Profile - Among the 56 patients analyzed for safety, 21 patients (37.5%) experienced Grade 3 or higher treatment-emergent adverse events, with one transient Grade 4 event reported [7] - Serious adverse events were reported in five patients, none of which were deemed related to the study medication [7] Efficacy Insights - The updated efficacy analysis suggests durable disease control and deepening of tumor response in the first 23 patients of Cohort 2 and both patients in Cohort 1 [6] - 19 of the 25 patients (76%) from the previous ESMO presentation were without progression and remained alive, including both patients in Cohort 1 [7] Future Plans - The company plans to submit additional efficacy data for the remaining patients in Cohort 2 and eight patients in Cohort 3 to more medical conferences in 2026, along with regulatory engagement [6][9] - The Chief Medical Officer emphasized the compelling clinical profile of VMT-α-NET and the completion of DLT assessment for the higher dose cohort, allowing for the enrollment of more patients [8]